Micreos

Micreos is a platform biotech company founded in 2006, with its headquarters in Switzerland. The company focuses on discovering and developing recombinant proteins for chronic Dermatology and Oncology conditions. Micreos is making strides in clinical-stage pharmaceutical biotech, with a vision to positively impact patient care and address global health care systems' concerns about antimicrobial resistance (AMR). Micreos' unique capability in modular engineering to optimize enzyme therapeutics has led to the development of three endolysin-based investigational antimicrobials. These antimicrobials target the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology, and bloodstream infections. The company's mission is to combat harmful bacteria in an era of antimicrobial resistance. Micreos recently secured a significant €25.00M Venture Round investment on 25 October 2022. Micreos' innovative approach to selectively killing only harmful bacteria while preserving the health-enhancing microbiome sets it apart in the biotechnology and healthcare industries. The company's commitment to developing medicinal solutions and forging partnerships across medicine demonstrates its potential to drive meaningful change in the fight against antimicrobial resistance. Overall, Micreos stands at the forefront of biotech innovation, poised to make a significant impact in improving patient outcomes and global healthcare systems.